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846-2 Should Volume Influence Patient Choice of Hospital for 
Aortic Valve Replacement?
Karl F. Welke, Mary S. Vaughn Sarrazin, Gary E. Rosenthal, University of Iowa Hosptials 
and Clinics, Iowa City, IA
Background: While prior research has found an inverse relationship between hospital
volume and mortality after aortic valve replacement (AVR), the use of volume as a proxy
for quality and a means for selecting hospitals is controversial. The purpose of this study
is to assess the suitability of hospital volume as predictor of mortality after AVR.
Methods: We performed a prospective cohort study of all 157,065 Medicare patients 65
years and older undergoing AVR in 1062 US hospitals during 1994-99. The study popula-
tion was categorized into quintiles, based on hospital Medicare AVR volume: very low
(<23/yr), low (23-39/yr), medium (40-63/yr), high (64-100/yr), and very high (>100/yr).
Logistic regression assessed the relationship between hospital volume and mortality (in-
hospital or within 30 days), adjusting for demographic and clinical risk factors. ROC curve
area assessed the discrimination of hospital volume.
Results: Mortality was higher (P<0.001) at very low volume hospitals (9.3%) than at low
(8.3%), medium (8.1%), high (7.6%), and very high volume hospitals (6.7%). However,
the range in mortality for hospitals within the 5 groups was substantial: 0-100% at very
low, 1-18% at low, 1-17% at medium, 3-18% at high, and 4-13% at very high volume hos-
pitals. Moreover, volume alone was a poor discriminator of mortality (ROC curve area =
0.53). Age (0.56) and female gender (0.54) were better discriminators of mortality than
volume.
Conclusions: While mortality was generally lower at high-volume hospitals, wide varia-
tion existed in mortality rates among hospitals with similar volumes. Volume alone, as a
discriminator of mortality, is only slightly better than a coin flip (ROC curve area of 0.50).
Patients selecting a hospital for AVR should consider a variety of factors and should not
expect choosing a higher volume hospital to significantly impact their individual mortality
risk.
2:30 p.m.
846-3 Potential Impact of MADIT II and the Centers for 
Medicaid Services Criteria on Care of Patients 
Diagnosed With Myocardial Infarction
Richard F. Otten, Eva M. Kline-Rogers, Jianming Fang, Darryl A. Elmouchi, Aman 
Chugh, Firas Al-Marayati, Frank Pelosi, Jr., Kim A. Eagle, University of Michigan Health 
System, Ann Arbor, MI
Background: The Centers for Medicare and Medicaid Services’ (CMS) updated policy
toward ICD implantation includes MADIT II criteria, but only in patients with a QRS>120
ms. We assessed the potential impact of MADIT II and CMS criteria on the care of acute
coronary syndrome (ACS) patients at our institution.
Methods: We evaluated 1370 of 1713 consecutive patients admitted for ACS 1/99-4/02
who had 6 month follow-up. We estimated the number of patients who would have quali-
fied for an ICD based on MADIT II criteria. By applying the CMS criteria of a QRS>120
ms, we compared 6 month outcomes between those patients who qualified by MADIT II
criteria with a QRS<120 ms to those who would have qualified by CMS criteria. Esti-
mated annual institutional costs and the potential number of deaths averted with each
strategy (based on Medicare reimbursement of $47,147 and MADIT II mortality data)
were evaluated.
Results 
Conclusions: A substantial percentage of ACS patients would have qualified for an ICD
based on MADIT II. Although there is no significant difference in death or rehospitaliza-
tion between the QRS groups, a considerable fraction of each group experience relatively
high rates of events compared to the all other ACS group. By limiting ICD’s to CMS crite-
ria, we would have seen a 57% reduction in ICD’s but at a potential price of missing
nearly half of the estimated arrhythmic deaths seen at 6 months. This simulated applica-
tion of the CMS criteria serves to illustrate the tradeoffs in applying this technology to
patients in the U.S.
2:45 p.m.
846-4 Predischarge Echocardiography Improves Outcomes 
After Congenital Heart Surgery
Pirooz Eghtesady, Martha W. Willis, Jareen Meinzen-Derr, Thomas Kimball, Eric 
Michelfelder, Jr., Linda Cripe, Jeffrey Pearl, Peter Manning, Children's Hospital Medical 
Center, Cincinnati, OH
Intraoperative transesophageal echocardiography (TEE) is accepted as a valuable tech-
nique for assessment of outcomes after congenital heart surgery. Many clinicians also
obtain additional transthoracic echocardiograms (TTE) prior to hospital discharge.This
practice is based on the premise that significant findings may be discovered that could
impact patient outcomes. It is unknown if such practices improve quality of care. We set
out to discover the utility of predischarge TTE in addition to intraoperative TEE after con-
genital heart surgery. We hypothesized that routine predischarge TTEs would not yield
significant differences from intraoperative TEE and would only alter treatment for a few
children.
We prospectively studied children who underwent cardiac surgery at a Midwest children’s
hospital from January to September 2003(n=124). Intraoperative TEEs were performed
on all patients and compared to predischarge TTE. We classified predischarge TTE find-
ings as “no change”, “improved”, or “worse”. Alterations in management were defined as
medication alterations, interventions or delayed discharges. The median age for the sub-
jects was 14 months (range 3 days-20.5 years). The median length of time from surgery
to TTE was 4 days (range 1-22days).
Among the children, 69% had an intraoperative TEE (n=85) and 79% had a predischarge
TTE (n=98). Over half of the children received both a TEE and TTE (63%), with 76% of
this subgroup (n=59) showing new findings (p<0.0001). Further, among these children,
39 (66%) showed deterioration in echocardiogram findings (“worse group”). Of these,
18% (n=7) had significant alteration in management. In total, 9% of patients had alter-
ation of management. The median age of children with a “worse” finding trended lower
than those who did not (10 mos vs. 39 mos, p=.13).
In conclusion, our results contradicted our original hypothesis. We found that pre-
discharge TTE identifies a significant number of new findings in comparison to
intraoperative TEE. These findings influence the management of a substantial number
of patients and leads to improved outcomes. In addition, these findings may impact follow
up care and long term outcomes.
3:00 p.m.
846-5 Improvement Initiatives Should Specifically Target 
Patients Admitted With Acute Myocardial Infarction 
Who Undergo Coronary Artery Bypass Surgery Before 
Hospital Discharge: Lessons From the Guidelines 
Applied in Practice Projects
Rajhendra H. Mehta, Anthony C. DeFranco, Cecelia K. Montoye, Canopy Roychoudhury, 
Benrong Chen, Patricia L. Baker, Arthur L. Riba, Kim A. Eagle, On behalf of the ACC 
GAP Steering Committee, University of Michigan, Ann Arbor, MI
Background: Patients admitted with acute myocardial infarction (AMI) may require coro-
nary artery bypass surgery (CABG) before hospital discharge. The Guidelines Applied in
Practice (GAP), a quality improvement initiative, has provided a mechanism for improving
the quality of care for patients with AMI. However, the influence of such an initiative on
enhancing evidence-based therapies among patients admitted for AMI who undergo
CABG before their hospital discharge is not known.
Methods: Thirty-three hospitals participated in three American College of Cardiology
GAP projects between 1999 and 2002. We compared the adherence to key discharge
indicators pre- and post GAP interventions in patients with AMI who underwent CABG
before hospital discharge versus those that did not undergo CABG. We also compared
the rates of adherence between the CABG and no-CABG groups following GAP to see if
these rates were similar in the two cohorts.
Results: The proportion of patients undergoing CABG before hospital discharge in the
baseline sample was 8% (110/1368) and in the remeasurement sample 9.3% (138/
1489). A trend towards improvement in adherence to most quality indicators was seen
following GAP for both groups of patients. Nevertheless, compared to AMI patients who
did not undergo surgical coronary revascularization, the ideal patients that required
CABG showed similar rates of adherence to aspirin (87.4% vs. 90.4%, p=0.39), beta-
blockers (92.1% vs. 91.5%, p=0.89), smoking cessation counseling (74.6% vs. 66.4%,
p=0.19), and dietary counseling (72.9% vs. 74.7%, p=0.77) but had significantly lower
rates for the use of angiotensin converting enzyme inhibitors (64.6% vs. 83.7%, p=0.008)
and cholesterol lowering agents (55.4% vs. 81.1%, p < 0.001). This lower compliance
with key indicators in CABG patients at discharge paralleled the low use of discharge
tools in these patients.
Conclusions: Our data suggests that patients admitted for AMI undergoing CABG
should be targeted specifically for quality improvement with systematic use of tools to
effectively enhance the adherence to key quality of care indicators in these patients.
3:15 p.m.
846-6 Amiodarone Reduces Major Cardiovascular Morbidity 
After Cardiac Surgery: Results of a Meta-Analysis
Johan D. Aasbo, Andrew T. Lawrence, Robert McNutt, Michael H. Kim, Richard G. 
Trohman, Rush University Medical Center, Chicago, IL
Background: Atrial fibrillation/flutter (AF/AFL) has an incidence as high as 40% following
coronary artery bypass grafting and 60% following valve surgery. Post cardiac surgery
AF/AFL has been associated with increased incidences of ventricular tachycardia and
Any QRS QRS<120 QRS>120 All other ACS P
#Qualifying pts 140 (10%) 80 (6%) 60 (4%) 1230
Annual Cost ($000) 1,731 742
%Death 20.3% 25.5% ------ .49
20.3% ------ 8.4% <.05
------ 25.5% 8.4% <.05
%Rehosp. 35.0% 44.2% ------ .35
35.0% ------ 27.1% .18
------ 44.2% 27.1% <.05
#arrhythmic deaths 
prevented/yr
.40 .21 .19
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fibrillation (VT/VF), post-operative stroke (CVA), and post-operative myocardial infarction
(MI).
Methods: We conducted a meta-analysis to assess the effect of peri-operative amio-
darone on the incidence of morbidity and mortality. MEDLINE, CINAHL, Cochrane Cen-
tral Register of Controlled Trials, and EMBASE databases were searched through 5/2003
with the terms atrial fibrillation, amiodarone and surgery. Inclusion criteria were random-
ized controlled double-blind study design and primary outcome designated as incidence
of AF/AFL. AF/AFL, VT/VF, CVA, MI, and mortality data were pooled using the DerSimo-
nian-Laird method with a random effects model. Trial heterogeneity was assessed via the
Woolf Q statistic, and publication bias was assessed with Kendall’s test on standardized
effect vs. variance.
Results: Eight randomized controlled double blind placebo trials with a total of 1,527
patients were included in our analysis of the incidence of AF/AFL and mortality. Of these,
six trials (1,184 patients) reported data on VT/VF, CVA, and MI. Heterogeneity and publi-
cation bias were not detected. Amiodarone significantly decreased the incidence of AF/
AFL [odds ratio 0.539, 95% CI (0.428, 0.678), P<0.0001], VT/VF [odds ratio 0.308, 95%
CI (0.164, 0.579), P=0.0003], and CVA [odds ratio 0.434, 95% CI (0.203, 0.929),
P=0.0315], when compared to placebo. Amiodarone did not significantly decrease the
incidence of MI [odds ratio 0.821, 95% CI (0.265, 2.543), P=0.732] and had no impact on
mortality [odds ratio 1.043, 95% CI (0.460, 2.370), P=0.919].
Conclusion: Amiodarone significantly reduced not only the incidence of AF/AFL, but also
of VT/VF and CVA. This study has important clinical implications and illustrates the need
for future prospective studies adequately powered to detect reductions in cardiovascular
morbidity and mortality.
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1172-67 Use of Administrative Databases May Lead to Incorrect 
Estimates of the Effects of Nonaspirin Nonsteroidal 
Anti-Inflammatory Drugs on MIyocardial Infarction Risk
Stephen E. Kimmel, Jesse A. Berlin, Jane Jaskowiak, Lori Kishel, Brian L. Strom, 
University of Pennsylvania School of Medicine, Philadelphia, PA
Background: Studies using administrative, prescription databases have generally shown
no effect of most nonselective non-aspirin nonsteroidal anti-inflammatory drugs (NAN-
SAIDs) on cardiovascular risk. We analyzed data from a study that specifically addressed
the biases inherent in using prescription databases to determine the effect of these
potential biases.
Methods: In our case-control study of NANSAIDs and first MI, we determined the odds
ratio for prescription (Rx) NANSAIDs versus non-users on MI risk as follows: (1) Replicat-
ing administrative database studies by: including over-the-counter (OTC) NANSAID
users as “non-users,” not excluding aspirin (ASA) users, and not adjusting for confound-
ers typically unavailable in administrative databases (smoking, family history, body mass
index, education, and physical activity). (2) Analysis #1 after removing OTC NANSAIDs
from the “non-user” category. (3) Analysis #2, adding adjustment for the confounders
listed above. (4) Analysis #3 plus excluding ASA users.
Results: OTC NANSAIDs accounted for 79% of all NANSAID use. ASA use was 28%.
Replication of administrative database analyses led to a null result (table). As we
removed each potential bias from our study, the OR moved further from 1.0 and indicated
a significant benefit of NANSAIDS in the fully adjusted analysis (#4).
Conclusion: The inability to measure OTC NANSAIDs, exclude ASA users, and adjust
for confounding may bias studies of prescription NANSAIDs and MI towards showing no
effect.
1172-68 Does Statin Therapy Reduce Contrast-Induced 
Nephropathy? An Analysis From a Large Regional 
Registry of Contemporary Percutaneous Interventions
Sanjaya Khanal, Nizar Attallah, Dean E. Smith, Eva Kline-Rogers, David Share, Michael 
J. O'Donnell, Mauro Moscucci, Henry Ford Hopsital, Detroit, MI, University of Michigan, 
Ann Arbor, MI
Background: Intravascular administration of contrast media can have nephrotoxic
effects particularly in patients with baseline renal insufficiency. Along with lowering serum
cholesterol, statins have pleiotropic effects in the vasculature. It is unclear whether statin
use has a protective effect against contrast-induced nephropathy (CN).
Methods: We evaluated 29,409 patients who had both baseline pre-procedure and peak
post-procedure serum creatinine measured at the time of their percutaneous coronary
intervention (PCI). Baseline demographics and creatinine profile before and after the pro-
cedure were compared between patients who received pre-procedure statins and those
who did not. CN was defined as increase in serum creatinine of >0.5 mg/dl.
Results: Baseline clinical characteristics were similar between the 2 groups (table).
When compared to patients who did not receive pre-procedure statins, patients on pre-
procedure statins had a lower incidence of CN (4.9 vs. 6.8, p<0.0001) and a trend
towards reducion of nephropathy requiring dialysis (0.4 vs. 0.6, p=0.07). After adjust-
ments for comorbidities, pre-procedure statin use was associated with a significant
reduction in CN (OR 0.81, 95% CI 0.72-0.92, p=0.0009).
Conclusions: Pre-procedure statin use is associated with significant reduction in CN
after contemporary PCI.
1172-69 Early Use of Small Molecule Platelet Glycoprotein IIb/IIIa 
Inhibitors for All Acute Coronary Syndrome Patients Is 
Superior to Selective Use of Abciximab for Only Those 
Requiring Percutaneous Coronary Interventions
Ruchira Glaser, Henry Glick, Howard C. Herrmann, Stephen E. Kimmel, University of 
Pennsylvania, Philadelphia, PA
Background: Selective use of medication may be important when several competing
therapies are available. Tirofiban and eptifibatide are small molecule platelet GP IIb/IIIa
inhibitors with benefit in acute coronary syndromes (ACS), but may not be as effective as
abciximab during percutaneous coronary intervention (PCI). However, abciximab does
not have proven efficacy in medical management of patients with ACS. No prior study
has attempted to balance the competing benefits of a strategy of giving all ACS patients a
small molecule versus a strategy of using abciximab only if a patient undergoes PCI. 
Methods: A decision analysis examined two treatment options and estimated under
what conditions one strategy was superior to another. The two strategies were (1) treat
all ACS patients initially with a small molecule GP IIb/IIIa inhibitor or (2) selectively use
abciximab only in ACS patients who ultimately undergo PCI. Sensitivity analyses were
performed over a wide range of assumptions. The primary outcome was life expectancy,
and cost effectiveness and bleeding were a secondary outcomes.
Results: The strategy of general use of a small molecule GP IIb/IIIa inhibitor on presen-
tation with ACS resulted in an average life expectancy of 15.93 years, compared with
15.71 years for selective use (life years savings of 0.22 years). The superiority of the gen-
eral use strategy persisted over all but extremes in sensitivity analyses. Preliminary cost
analyses showed general use as economically attractive, with cost per life year of less
than $50,000 over a wide range of assumptions. There was a similar likelihood of major
bleeding for patients with general use v. selective (6.5% v 6.1%).
Conclusion: General use of early GP IIb/IIIa inhibition in all patients presenting with
ACS leads to better outcomes than selective use. A selective use strategy may be supe-
rior only if a patient is extremely likely to undergo PCI (over 90%)or there is virtually no
reduction of events in medically managed patients receiving GP IIb/IIIa inhibition. When
faced with these competing strategies, the clinician should consider the significant, cost
effective benefits to general use of small molecule platelet GP IIb/IIIa inhibitors in ACS.
1172-70 Tolerability, Safety, and Efficacy of Beta-Blockade in 
Black Patients With Heart Failure in the Community 
Setting: Insights From a Large Prospective Beta-
Blocker Registry
William T. Abraham, Barry M. Massie, Mary Ann Lukas, Sandra R. Lottes, Jeanenne J. 
Nelson, Michael B. Fowler, Barry Greenberg, Edward M. Gilbert, Joseph A. Franciosa, 
and the COHERE Participant Physicians, GlaxoSmithKline Pharmaceuticals, 
Philadelphia, PA
Background: Conflicting data exist regarding the tolerability and efficacy of beta-block-
ade in Black patients with heart failure (HF). In randomized controlled trials bucindolol
appeared to worsen clinical outcome in Blacks while carvedilol apparently improved out-
come comparably to White patients.
Methods: The Coreg Heart Failure Registry (COHERE) prospectively evaluated the
early and 1-yr tolerability, safety, and efficacy of carvedilol in 4,280 HF patients treated in
the community setting.
Results: Prior to initiation of carvedilol, Black patients (n=523) differed from White
patients (n=3,433) in demonstrating more severe symptoms (NYHA Class III/IV, 44.3% vs
35.3%, p<0.001), more diabetes (37.1% vs 30.3%, p=0.002), less history of ischemic
Effects of Adjustment
Analysis
(see text)
Odds Ratio (95% CI)
#1 Replicating Administrative Database Analysis 1.0 (0.7-1.3)
#2 0.9 (0.7-1.1)
#3 0.8 (0.6-1.0)
#4 - Fully adjusted 0.7 (0.5-0.9)
Statin use and CN
Pre-statins No Pre-statins
Variable N=11,017 N=18,392 p-value
Age (mean (SD)), yrs 63.6 63.6 0.78
Female (%) 33.9 35.4 0.008
Baseline Creatinine (mean mg/dl) 1.2 1.2 0.50
Percent with Baseline Creatinine 1.5+mg/dl 12.9 12.6 0.54
Percent with Baseline Creatinine 2.0+mg/dl 4.8 5.0 0.42
Peak Creatinine (mean mg/dl) 1.3 1.3 0.30
Peak Creatinine 1.5+mg/dl 14.5 15.8 0.003
Peak Creatinine 2.0+mg/dl 6.6 7.9 <0.0001
Renal Failure Requiring Dialysis 0.4 0.6 0.07
Contrast Nephropathy 4.9 6.8 <0.0001
